<DOC>
	<DOC>NCT01281631</DOC>
	<brief_summary>This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study of NP001 in subjects with ALS.</brief_summary>
	<brief_title>A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
	<detailed_description>This is a randomized, double-blind, placebo-controlled study of NP001 in subjects with ALS conducted in multiple centers. Drug or placebo will be given intravenously. Approximately 105 subjects will be enrolled. Subjects will be allocated (1:1:1) to placebo and 2 dose levels of NP001.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Subjects with sporadic or familial ALS classified as definite, probable, or laboratorysupported probable ALS according to the revised El Escorial criteria. A list of key criteria is listed below: Onset of symptoms less than 3 years prior to study entry. Forced Vital Capacity (FVC) at least 70% of that predicted for age and height. Stable dose of riluzole if undergoing treatment with this agent. For females: Not be of childbearing potential or agree to use adequate birth control during the study. Unstable medical condition(s) other than ALS. Life expectancy of less than 6 months. Require lifesustaining interventions for the 6 months following randomization. Have a tracheotomy or be using ventilatory assistance [including Bilevel Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP)]. Active pulmonary disease. Immune modulator therapy within 12 weeks of study entry or participation in studies of other agents within the last 4 weeks prior to the randomization.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ALS</keyword>
</DOC>